ConductScience.org, home

Paper23908178

Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications.

Montemurro F and 2 others. Ann Oncol, 2013. Cited by 120 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications. Papers, record 23908178. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23908178

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications.
PubMed
Journal
Ann Oncol
PubMed
Year
2013
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
120
iCite
Relative citation ratio, by iCite
3.16
iCite
Revised in PubMed
2026-01-28
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Montemurro FF
2Di Cosimo SS
3Arpino GG

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Breast NeoplasmsMajor topic
Molecular Targeted TherapyMajor topic
Erb-b2 Receptor Tyrosine KinasesMajor topic
Antineoplastic Combined Chemotherapy Protocols
Drug Resistance, Neoplasm
Female
Humans
Receptors, Estrogen
Receptors, Progesterone

Source PubMed

Download CSV of topics

Cited by80

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 120 citations.

PMIDTitleJournalYearIn PapersSource
42170572Can neoadjuvant chemotherapy be replaced with immune checkpoint blockade combined with dual anti-HER2 antibodies for HER2-enriched breast cancer?Transl Breast Cancer Res2026https://conductscience.org/library/papers/42170572PubMed
41899145Real-World Outcomes of Neoadjuvant Dual Blockade in HER2-Positive Breast Cancer: The Role of Tumor Biology and pCR.J Clin Med2026https://conductscience.org/library/papers/41899145PubMed
41584604Maintenance therapy in hormone receptor-positive and human epidermal growth factor receptor 2-positive metastatic breast cancer: a real-world multicenter retrospective study.Front Oncol2025https://conductscience.org/library/papers/41584604PubMed
41547594Optimizing adjuvant endocrine therapy in premenopausal patients with HER2-positive, hormone receptor-positive breast cancer.Breast2026https://conductscience.org/library/papers/41547594PubMed
41446275Contrasting low- and high-resolution features for HER2 scoring using deep learning.J Pathol Inform2025https://conductscience.org/library/papers/41446275PubMed
41402571HER2 expression in breast cancer: evidence gaps and challenges.NPJ Precis Oncol2025https://conductscience.org/library/papers/41402571PubMed
41023545Contemporary Nodal Management and Overall Survival of Older Patients with HR-/HER2+ Breast Cancer.Ann Surg Oncol2026https://conductscience.org/library/papers/41023545PubMed
40720499Response Gene to Complement 32 promotes cell proliferation and tamoxifen resistance in breast cancer via elevated FoxM1 expression.PLoS One2025https://conductscience.org/library/papers/40720499PubMed
40243160Characterisation of HER2-Driven Morphometric Signature in Breast Cancer and Prediction of Risk of Recurrence.Cancer Med2025https://conductscience.org/library/papers/40243160PubMed
40126169Molecular shifts in breast cancer following neoadjuvant chemotherapy: a prospective study and review of literature.Future Oncol2025https://conductscience.org/library/papers/40126169PubMed
40123585Innovative Approaches for Molecular Targeted Therapy of Breast Cancer: Interfering with Various Pathway Signaling.Int J Mol Cell Med2025https://conductscience.org/library/papers/40123585PubMed
39695741ERBB2/HOXB13 co-amplification with interstitial loss of BRCA1 defines a unique subset of breast cancers.Breast Cancer Res2024https://conductscience.org/library/papers/39695741PubMed
39399377Targeting LINC00665/miR-199b-5p/SERPINE1 axis to inhibit trastuzumab resistance and tumorigenesis of gastric cancer via PI3K/AKt pathway.Noncoding RNA Res2025https://conductscience.org/library/papers/39399377PubMed
39355199Investigating the Correlation Between Long-Term Response in Patients with Metastatic HER2+ Breast Cancer and the Activity of Regulatory T Cells: A Retrospective Study.Breast Cancer (Dove Med Press)2024https://conductscience.org/library/papers/39355199PubMed
39009909Synthesis, characterization and bioactivity of new pyridine-2(H)-one, nicotinonitrile, and furo[2,3-b]pyridine derivatives.Mol Divers2025https://conductscience.org/library/papers/39009909PubMed
38667310Three-Dimensional Cultivation a Valuable Tool for Modelling Canine Mammary Gland Tumour Behaviour In Vitro.Cells2024https://conductscience.org/library/papers/38667310PubMed
38231460Clinicopathological differences and survival benefit in ER+/PR+/HER2+ vs ER+/PR-/HER2+ breast cancer subtypes.Breast Cancer2024https://conductscience.org/library/papers/38231460PubMed
37740038Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level.Br J Cancer2023https://conductscience.org/library/papers/37740038PubMed
37600670HER2-Low Breast Cancer: Current Landscape and Future Prospects.Breast Cancer (Dove Med Press)2023https://conductscience.org/library/papers/37600670PubMed
37363965Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer.Clin Cancer Res2023https://conductscience.org/library/papers/37363965PubMed

See all 80 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ERBB22064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
NR4A13164PubTator's text mininghttps://conductscience.org/library/genes/3164NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/23908178

GET https://conductscience.org/api/papers/v1/23908178/cited_by?page=2